A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4
Launched by HOFFMANN-LA ROCHE · Jan 26, 2010
Trial Information
Current as of April 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adult patients, 18-70 years of age
- • hepatitis C, genotype 1 or 4, of over 6 months duration
- • treatment-naïve
- • negative pregnancy test; female patients of childbearing age and male patients with female partners of childbearing age must use two forms of contraception during treatment and following the last dose of ribavirin in accordance with locally approved label for ribavirin
- Exclusion Criteria:
- • pregnant or breast feeding females or male partners of pregnant females
- • previous interferon or ribavirin based therapy or investigational anti-HCV agent
- • systemic antiviral therapy with established or perceived activity against HCV \</=3 months prior to first dose of study drug
- • hepatitis A or B, or HIV infection
- • history or evidence of medical condition associated with chronic liver disease other than HCV
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Ottawa, Ontario, Canada
Chicago, Illinois, United States
Kansas City, Kansas, United States
Winnipeg, Manitoba, Canada
Houston, Texas, United States
Honolulu, Hawaii, United States
London, Ontario, Canada
Atlanta, Georgia, United States
Nashville, Tennessee, United States
La Jolla, California, United States
Indianapolis, Indiana, United States
Albuquerque, New Mexico, United States
Bradenton, Florida, United States
Bronx, New York, United States
New York, New York, United States
Lebanon, New Hampshire, United States
Columbia, South Carolina, United States
Vancouver, British Columbia, Canada
Calgary, Alberta, Canada
San Antonio, Texas, United States
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials